



Maxor⁺

PHARMACY BENEFIT MANAGEMENT SERVICES

BIOSIMILAR STRATEGY

Biosimilars have been around since 2006, with the first U.S. approval in 2015.* Historically, it has taken two to three years for biosimilar products to gain a significant amount of market share. New-to-market biosimilar products in 2023 captured approximately 2% market share since launching.

Biosimilars represent both a significant opportunity and challenge for the biopharmaceutical industry, especially for blockbuster drugs. Biosimilars could offer substantial cost savings and improved patient outcomes, but they also face regulatory, legal, and commercial hurdles. The Food and Drug Administration, for example, regulates biosimilars on a federal level, but there are other regulations that vary from state to state.

MaxorPlus is continuously preparing for market landscape changes, evaluating the pipeline to identify trends, and vetting manufacturers in the biosimilar space. Pharmacy benefit managers can partner with specialty pharmacies to deliver your benefit design strategy, building a plan that works for your specific needs.

Starting July 1, 2025

- Humira® will no longer be included on the Advantage and Focus formularies, and Humira will be non-preferred on the Preferred formulary for all members.
- Stelara® will no longer be included on the Advantage and Focus formularies for members new to therapy.

Starting January 1, 2026

- Stelara will no longer be included on the Advantage and Focus formularies for all members.

Source

* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013845/>

